LolCDE-IN-4 (Compound 1) demonstrates antibacterial potency by inhibiting the LolCDE complex and disrupting the release of lipoproteins from the inner membrane, showing efficacy against gram-negative bacteria such as Escherichia coli (MIC of 0.25-32 µg/ml) and Haemophilus influenzae .